Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 30, 2017
Event: Entry into a Material Definitive Agreement (Binding Term Sheet) with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to amend existing license and asset purchase agreements.
Key Financial Metrics and Agreements
This filing details a restructuring of financial obligations and royalty terms rather than reporting standard periodic financial results (revenue, profit, cash flow). Key financial terms established in the Term Sheet include:
- Milestone Payments: Eliminated in their entirety under the Cannabis License Agreement, Diabetes License Agreement, and Asset Purchase Agreement.
- Royalty Rates (Gross Sales): Reduced to 4% across the relevant agreements.
- Sublicense Royalties: Set at 20% of amounts received by the Company from sublicensees. If sublicensee payments are 4% or less of gross sales, Austrianova receives 50% of the Company's receipt (up to 2%) plus 20% of any amount over 4%.
- Other Consideration: Austrianova to receive 50% of any financial or non-financial consideration from sublicensees of the Cell-in-a-Box technology.
- Upfront Cash Payment: Company to pay Austrianova Singapore $150,000 per month for six months.
- Executive Compensation: Chief Scientific Officer Prof. Walter H. Günzburg will receive no cash compensation for six months starting September 1, 2017.
Material Changes Versus Prior Period
The Term Sheet represents a significant modification to prior contractual obligations:
- Debt/Liability Reduction: Complete removal of previously agreed milestone payments.
- Scope Expansion: The Diabetes License Agreement scope is expanded to include all cell types and lines (primary, mortal, immortal, stem cells) designed to produce insulin.
- Intellectual Property Rights: Company granted a 5-year right of first refusal on the sale of the "Cell-in-a-Box" tradename and associated technologies (excluding "Bac-in-a-Box").
- Non-Solicitation: Austrianova agreed not to solicit inquiries regarding the acquisition of Cell-in-a-Box for one year.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) regarding the Term Sheet but does not provide specific forward-looking financial guidance or revenue projections within the text of the 8-K itself.
Risks and Contingencies: The summary of the Term Sheet is subject to the full text of the agreement filed as Exhibit 10.1. The agreement involves complex royalty calculations based on sublicensee performance and future potential sales of intellectual property.
Investor Verification Checklist
- Verify the full text of the Binding Term Sheet (Exhibit 10.1) for conditions precedent to the elimination of milestone payments.
- Confirm the Company's current cash position to ensure it can meet the $150,000 monthly payment obligation for six months.
- Review the specific definitions of "Associated Technologies" to understand the scope of the right of first refusal.
- Assess the impact of the expanded Diabetes License Agreement scope on future R&D costs and potential revenue streams.
- Check the press release (Exhibit 99.1) for additional context on the strategic rationale for these amendments.